insulin icodec/semaglutide Once‑weekly IcoSema versus once‑weekly icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial Full article: Advances in insulin:

Few of the reports looked into the heart of the case: The Pentagons 2025 decision to end coverage of GLP-1 drugs under TRICARE For Life while maintaining it in similar circumstances for other TRICARE users

Aljabali AAA, Obeid MA, Gammoh O, El-Tanani M, Mishra V, Mishra Y, et al

Practical Reasons for Schedule Adjustments and Safe Approaches Life circumstanceswork travel, appointment scheduling, or vacationoften prompt timing questions

Keep your lips looking smooth, comfortable, and well cared for with Glutanex Lip Glow Balm Clear, a lightweight lip balm designed to provide lasting moisture and a natural glossy finish

Type 2 diabetes with cardiovascular risk Injectable semaglutide has direct cardiovascular outcome data in patients with established cardiovascular disease and overweight or obesity, from the SELECT trial

Regular monitoring of inflammatory markers, disease activity scores, and functional status remains essential regardless of concurrent GLP-1 use